Patent 9597348 was granted and assigned to Epizyme on March, 2017 by the United States Patent and Trademark Office.
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.